Show simple item record

dc.contributor.authorRossor, T
dc.contributor.authorYeh, EA
dc.contributor.authorKhakoo, Y
dc.contributor.authorAngelini, P
dc.contributor.authorHemingway, C
dc.contributor.authorIrani, SR
dc.contributor.authorSchleiermacher, G
dc.contributor.authorSantosh, P
dc.contributor.authorLotze, T
dc.contributor.authorDale, RC
dc.contributor.authorDeiva, K
dc.contributor.authorHero, B
dc.contributor.authorKlein, A
dc.contributor.authorde Alarcon, P
dc.contributor.authorGorman, MP
dc.contributor.authorMitchell, WG
dc.contributor.authorLim, M
dc.contributor.authorOMS Study Group,
dc.coverage.spatialUnited States
dc.date.accessioned2022-11-16T12:46:51Z
dc.date.available2022-11-16T12:46:51Z
dc.date.issued2022-05-01
dc.identifierARTN e1153
dc.identifier9/3/e1153
dc.identifier.citationNeurology: Neuroimmunology & Neuroinflammation, 2022, 9 (3), pp. e1153 -
dc.identifier.issn2332-7812
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5560
dc.identifier.eissn2332-7812
dc.identifier.eissn2332-7812
dc.identifier.doi10.1212/NXI.0000000000001153
dc.description.abstractBACKGROUND AND OBJECTIVES: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare disorder of the nervous system that classically presents with a combination of characteristic eye movement disorder and myoclonus, in addition to ataxia, irritability, and sleep disturbance. There is good evidence that OMAS is an immune-mediated condition that may be paraneoplastic in the context of neuroblastoma. This syndrome may be associated with long-term cognitive impairment, yet it remains unclear how this is influenced by disease course and treatment. Treatment is largely predicated on immune suppression, but there is limited evidence to indicate an optimal regimen. METHODS: Following an international multiprofessional workshop in 2004, a body of clinicians and scientists comprising the International OMS Study group continued to meet biennially in a joint professionals and family workshop focusing on pediatric OMAS. Seventeen years after publication of the first report, a writing group was convened to provide a clinical update on the definitions and clinical presentation of OMAS, biomarkers and the role of investigations in a child presenting with OMAS, treatment and management strategies including identification and support of long-term sequelae. RESULTS: The clinical criteria for diagnosis were reviewed, with a proposed approach to laboratory and radiologic investigation of a child presenting with possible OMAS. The evidence for an upfront vs escalating treatment regimen was reviewed, and a treatment algorithm proposed to recognize both these approaches. Importantly, recommendations on monitoring of immunotherapy response and longer-term follow-up based on an expert consensus are provided. DISCUSSION: OMAS is a rare neurologic condition that can be associated with poor cognitive outcomes. This report proposes an approach to investigation and treatment of children presenting with OMAS, based on expert international opinion recognizing the limited data available.
dc.formatElectronic-Print
dc.format.extente1153 -
dc.languageeng
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofNeurology: Neuroimmunology & Neuroinflammation
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAtaxia
dc.subjectChild
dc.subjectDisease Progression
dc.subjectHumans
dc.subjectInternationality
dc.subjectNeuroblastoma
dc.subjectOcular Motility Disorders
dc.subjectOpsoclonus-Myoclonus Syndrome
dc.titleDiagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.
dc.typeJournal Article
dcterms.dateAccepted2022-01-18
dc.date.updated2022-11-16T12:30:45Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1212/NXI.0000000000001153
rioxxterms.licenseref.startdate2022-05-01
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35260471
pubs.issue3
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1212/nxi.0000000000001153
pubs.volume9
dc.contributor.icrauthorAngelini, Paola
icr.provenanceDeposited by Paola Angelini on 2022-11-16. Deposit type is initial. No. of files: 1. Files: Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children An International Perspective. .pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/